

## **LECTURE 4**


### **HISTONE METHYLATION AND DNA METHYLATION**

## **LECTURE 4**

### **HISTONE METHYLATION MECHANISMS**




## HISTONE LYSINE AND ARGININE METHYL TRANSFERASES (HKMETs and HRMETs))



## HISTONE LYSINE METHYL TRANSFERASES (HKMETs)

all HKMETs contain a conserved SET domain that catalyzes the methylation of Lysines (K)  
(exception Dot1 – no SET domain)




50 SET domain proteins are  
Categorized according to sequence  
homology  
into 6 HKMET subfamilies

1. SET1 family
2. SET2 family
3. SUV39 family
4. EZH family
5. SMYD family
6. PRDM family
7. other SET domain HKMETs

50 SET domain proteins contain many  
other protein domains  
→ Interaction with other proteins or  
DNA

## HKMET HRMET SUBSTRATES ON HUMAN HISTONES

A



**HKMETS epigenetic writers are substrate specific and can result in gene repression but also gene activation**

→→→

**The epigenetic reader that binds to the modified histone K residue at the individual histone tail makes the difference**

**Effect on gene activity: Best studied examples of histone methylation:**

activation

repression

repression

activation

activation

repression

| Substrate | Histone lysine methyltransferases                    |
|-----------|--|
| H3K4      | SET9, SET1, MLL, ASH1L, SMYD3, PRDM9, SETMAR         |
| H3K9      | SUV39H1, SUV39H2, EHMT1, EHMT2, SETDB1, PRDM2, ASH1L |
| H3K27     | EZH2, EHMT2  |
| H3K36     | NSD1, SETD2/HYPB, SETMAR                             |
| H3K79     | DOT1L  |
| H4K20     | SET8, SUV420H1, SUV420H2, NSD1, ASH1L                |

Fig. 1. Histone modifications. (A) The modifications on human histones include methylation (Me) on arginine and lysine residues, acetylation (Ac) on lysine residues, phosphorylation (P) on serine and threonine residues and ubiquitination (Ub) on lysine residues. (B) The enzymes responsible for methylation of human histone lysine residues are listed according to their target sites. Histone lysine methyltransferases (HKMTs) are very specific but redundant in several cases.

Lecture 4 Histone methylation and DNA methylation

# HISTONE MODIFICATIONS AND EPIGENETIC READERS

**Protein domains that bind to histone mo**

The diagram illustrates the N-terminal tail of histone H3 and the various post-translational modifications (PTMs) it can undergo, along with the protein domains that recognize and bind to these modifications. The H3 tail is shown as a horizontal line with residues A1, R2, T3, K4, K9, S10, K14, R17, K18, K23, K27, S28, and K36 marked. PTMs are indicated by colored shapes: blue boxes for phosphorylated (ph) serine/threonine, orange triangles for acetylated (ac) lysine, and purple circles for methylated (me) lysine/arginine. Readers are shown as colored shapes with their specific binding domains listed: purple for methyl-binding, blue for phosphorylation-binding, and orange for acetylation-binding. The Nucleosome is shown as a grey cylinder with DNA strands on the right.

**Figure 1** Readers of histone PTMs. Recognition of the methylated (me) lysine, methylated (me) arginine, acetylated (ac) lysine and phosphorylated (ph) serine and threonine residues of the N-terminal histone H3 tail by indicated readers.

**Protein domains that bind to histone mo**

The diagram illustrates the N-terminal tail of histone H3 and the various post-translational modifications (PTMs) it can undergo, along with the protein domains that recognize and bind to these modifications. The H3 tail is shown as a horizontal line with residues A1, R2, T3, K4, K9, S10, K14, R17, K18, K23, K27, S28, and K36 marked. PTMs are indicated by colored shapes: blue boxes for phosphorylated (ph) serine/threonine, orange triangles for acetylated (ac) lysine, and purple circles for methylated (me) lysine/arginine. Readers are shown as colored shapes with their specific binding domains listed: purple for methyl-binding, blue for phosphorylation-binding, and orange for acetylation-binding. The Nucleosome is shown as a grey cylinder with DNA strands on the right.

**Figure 1** Readers of histone PTMs. Recognition of the methylated (me) lysine, methylated (me) arginine, acetylated (ac) lysine and phosphorylated (ph) serine and threonine residues of the N-terminal histone H3 tail by indicated readers.

A large number of proteins contain these protein domains:

- High complexity in gene regulation that
- Creation of large numbers of EPIGENOMES

A large number of proteins contain these protein domains:

- High complexity in gene regulation that
- Creation of large numbers of EPIGENOMES

A large number of proteins contain these protein domains:


- High complexity in gene regulation that
- Creation of large numbers of EPIGENOMES

| Recognition of                    | Reader        | Histone PTM                            |
|-----------------------------------|---------------|--|
| Methyllysine                      | ADD           | H3K9me3                                |
|                                   | Ankyrin       | H3K9me2, H3K9me1                       |
|                                   | BAH           | H4K20me2                               |
|                                   | Chromo-barrel | H3K36me3, H3K36me2, H4K20me1, H3K4me1  |
|                                   | Chromodomain  | H3K9me3, H3K9me2, H3K27me3, H3K27me2   |
|                                   | DCD           | H3K4me3, H3K4me2, H3K4me1              |
|                                   | MBT           | H3Kme1, H3Kme2, H4Kme1, H4Kme2         |
|                                   | PHD           | H3K4me3, H3K4me2, H3K9me3              |
|                                   | PWWP          | H3K36me3, H4K20me1, H4K20me3, H3K79me3 |
|                                   | TTD           | H3K4me3, H3K9me3, H4K20me2             |
|                                   | Tudor         | H3K36me3                               |
|                                   | WD40          | H3K27me3, H3K9me3                      |
|                                   | zf-CW         | H3K4me3                                |
| Methylarginine                    | ADD           | H4R3me2s                               |
|                                   | Tudor         | H3Rme2, H4Rme2                         |
|                                   | WD40          | H3R2me2                                |
| Acetyllysine                      | Bromodomain   | H3Kac, H4Kac, H2AKac, H2BKac           |
|                                   | DBD           | H3KacKac, H4KacKac                     |
|                                   | DPF           | H3Kac                                  |
|                                   | Double PH     | H3K56ac                                |
| Phosphoserine or phosphothreonine | 14-3-3        | H3S10ph, H3S28ph                       |
|                                   | BIR           | H3T3ph                                 |
|                                   | Tandem BRCT   | H2AXS139ph                             |
| Unmodified histone                | ADD           | H3un                                   |
|                                   | PHD           | H3un                                   |
|                                   | WD40          | H3un                                   |


| Recognition of                    | Reader        | Histone PTM                            |
|-----------------------------------|---------------|--|
| Methyllysine                      | ADD           | H3K9me3                                |
|                                   | Ankyrin       | H3K9me2, H3K9me1                       |
|                                   | BAH           | H4K20me2                               |
|                                   | Chromo-barrel | H3K36me3, H3K36me2, H4K20me1, H3K4me1  |
|                                   | Chromodomain  | H3K9me3, H3K9me2, H3K27me3, H3K27me2   |
|                                   | DCD           | H3K4me3, H3K4me2, H3K4me1              |
|                                   | MBT           | H3Kme1, H3Kme2, H4Kme1, H4Kme2         |
|                                   | PHD           | H3K4me3, H3K4me2, H3K9me3              |
|                                   | PWWP          | H3K36me3, H4K20me1, H4K20me3, H3K79me3 |
|                                   | TTD           | H3K4me3, H3K9me3, H4K20me2             |
|                                   | Tudor         | H3K36me3                               |
|                                   | WD40          | H3K27me3, H3K9me3                      |
|                                   | zf-CW         | H3K4me3                                |
| Methylarginine                    | ADD           | H4R3me2s                               |
|                                   | Tudor         | H3Rme2, H4Rme2                         |
|                                   | WD40          | H3R2me2                                |
| Acetyllysine                      | Bromodomain   | H3Kac, H4Kac, H2AKac, H2BKac           |
|                                   | DBD           | H3KacKac, H4KacKac                     |
|                                   | DPF           | H3Kac                                  |
|                                   | Double PH     | H3K56ac                                |
| Phosphoserine or phosphothreonine | 14-3-3        | H3S10ph, H3S28ph                       |
|                                   | BIR           | H3T3ph                                 |
|                                   | Tandem BRCT   | H2AXS139ph                             |
| Unmodified histone                | ADD           | H3un                                   |
|                                   | PHD           | H3un                                   |
|                                   | WD40          | H3un                                   |

## THE SET DOMAIN

### THE SET DOMAIN



### THE ACTIVE SITE IN THE SET DOMAIN



## THE BIOCHEMISTRY OF HISTONE LYSINE METHYLATION

The source of the methyl group is S-adenosyl-l-methionine (AdoMet) or (SAM), which is converted to S-adenosyl-l-homocysteine (AdoHcy) in the reaction.


S-Adenosyl methionine is a common cosubstrate involved in methyl group transfers, transsulfuration, and aminopropylation.

**SAM = enzymatic cofactor**


**SAM is after ATP the most commonly used cofactor used by the cell**

Although these anabolic reactions occur throughout the body, most **SAM is produced and consumed in the liver**. More than 40 methyl transfers from SAM are known, to various substrates such as nucleic acids, proteins, lipids and secondary metabolites. It is made from adenosine triphosphate (ATP) and methionine by methionine adenosyltransferase. SAM was first discovered in Italy by Giulio Cantoni in 1952.

S-adenosyl-l-methionine (AdoMet) or (SAM),



## THE BIOCHEMISTRY OF HISTONE LYSINE METHYLATION



### Catalytic mechanism

In order for the reaction to proceed, S-Adenosyl methionine (SAM) and the lysine residue of the substrate histone tail must first be bound and properly oriented in the catalytic pocket of the SET domain. Next, a **nearby tyrosine residue deprotonates the  $\epsilon$ -amino group of the lysine residue**. The lysine chain then makes a nucleophilic attack on the methyl group on the sulfur atom of the SAM molecule, transferring the methyl group to the lysine side chain.




## ENZYMATIC ASSAY TO DETECT KMTase ACTIVITY

Experiment:

Overexpression of **myc-tagged-SUV39H1 KMT** in Hela cells

Use an antibody to immunoprecipitate SUV39H1 → high concentration of SUV39H1


Incubate Immunoprecipitate with purified histones and S-adenosyl-[methyl-<sup>14</sup>C]-L-methionin as methyl donor



SET – domain is required for histone methyl transferases activity

- The SET domain of the SUV39H1 is required for histone methyltransferase activity and this enzyme methylates H3 at Lys9


S-adenosyl-L-methionine (AdoMet) or (SAM),






## HISTONE LYSINES CAN BE MONO- DI- AND TRI-METHYLATED

### lysine methylation



**ARE THERE KMTs THAT CREATE SPECIFIC METHYLATION LEVELS  
(mono-methylation, di-methylation, tri-methylation?)**

## SUBSTRATE SPECIFICITY OF HISTONE METHYL TRANSFERASES: AN EXAMPLE: THE HKMT SUV39H1




### **Suv39dn cells**

H3K9me1: increased and  
pattern similar to  
wt H3K9me3 (chromocenter)

H3K9me2: similar to wt

H3K9me3: strongly reduced; lost at chromocenters





### **Suv39dn cells**

H3K9me1: increased compared to wt

H3K9me2: similar to wt

H3K9me3: strongly reduced

## SUBSTRATE SPECIFICITY OF HISTONE METHYL TRANSFERASES: AN EXAMPLE: THE HKMT SUV39H1




The H3K9 specific KMTs G9a and GLP are the major H3K9me1 and H3K9me2 methyltransferases

The H3K9 specific KMTases Suv39h1 and Suv39h2 are the major H3K9me3 methyltransferases

Suv39h1 and Suv39h1 work best on H3K9me2

### H3K9 methylation



## EPIGENETIC READERS

### AN EXAMPLE: H3K9me3 and HP1





Table 1 Histone readers and their target PTMs

| Recognition of                    | Reader        | Histone PTM                            |
|-----------------------------------|---------------|--|
| Methyllysine                      | ADD           | H3K9me3                                |
|                                   | Ankyrin       | H3K9me2, H3K9me1                       |
|                                   | BAH           | H4K20me2                               |
|                                   | Chromo-barrel | H3K36me3, H3K36me2, H4K20me1, H3K4me1  |
|                                   | Chromodomain  | H3K9me3, H3K9me2, H3K27me3, H3K27me2   |
|                                   | DCD           | H3K4me3, H3K4me2, H3K4me1              |
|                                   | MBT           | H3Kme1, H3Kme2, H4Kme1, H4Kme2         |
|                                   | PHD           | H3K4me3, H3K4me2, H3K9me3              |
|                                   | PWWP          | H3K36me3, H4K20me1, H4K20me3, H3K79me3 |
|                                   | TTD           | H3K4me3, H3K9me3, H4K20me2             |
| Methylarginine                    | Tudor         | H3K36me3                               |
|                                   | WD40          | H3K27me3, H3K9me3                      |
|                                   | zf-CW         | H3K4me3                                |
|                                   | ADD           | H4R3me2s                               |
| Acetyllysine                      | Tudor         | H3Rme2, H4Rme2                         |
|                                   | WD40          | H3R2me2                                |
|                                   | Bromodomain   | H3Kac, H4Kac, H2AKac, H2BKac           |
|                                   | DBD           | H3KacKac, H4KacKac                     |
|                                   | DPF           | H3Kac                                  |
| Phosphoserine or phosphothreonine | Double PH     | H3K56ac                                |
|                                   | 14-3-3        | H3S10ph, H3S28ph                       |
|                                   | BIR           | H3T3ph                                 |
|                                   | Tandem BRCT   | H2AXS139ph                             |
| Unmodified histone                | ADD           | H3un                                   |
|                                   | PHD           | H3un                                   |
|                                   | WD40          | H3un                                   |

## EPIGENETIC READERS – IN VIVO EVIDENCE


### AN EXAMPLE: HP1 has high affinity for H3K9me3



A chromodomain (chromatin organization modifier) is a protein structural domain of about 40-50 amino acid residues commonly found in proteins associated with the remodeling and manipulation of chromatin. The domain is highly conserved among both plants and animals, and is represented in a large number of different proteins in many genomes, such as that of the mouse. Chromodomain-containing proteins also bind methylated histones and appear in the RNA-induced transcriptional silencing complex.

YELLOW: histone tail


RODs: Interacting aminoacids of HP1



**Loss of Suv39h1/2:**  
**reduced**  
 (2 slides earlier)  
**and delocalized**  
 (this slide) **H3K9me3.**


Consequence:  
**HP1 is also**  
**delocalized!!!!**

## HISTONE LYSINE AND ARGININE METHYL TRANSFERASES (HKMETs and HRMETs))



## HISTONE ARGININE METHYL TRANSFERASES (HRMETs)



### Family of PRMTs: Protein Arginine (R ) methyl-transferases



**PRMTs** have a MTase domain that is Different from the SET domain!!!

**Conserved core:**

- MTase domain: catalyzes methylation of R
- Beta barrel domain: Important for dimerization of PRMTs



### PRMTs

- Type I PRMTs: need to dimerize to be functional
- Type II PRMTs: form larger complexes – dimers interact to form tetramers, other proteins can interact



## THE BIOCHEMISTRY OF HISTONE ARGININE METHYLATION

### Methyl transfer reactions catalyzed by AdoMet-dependent PRMTs.

Example: PRMT1


The reacting arginine substrate acts by nucleophilic attack on the methyl group present on AdoMet.

The reaction has been proposed to involve 3 key conserved residues in the active site of PRMT1: Arg-54, Glu-144, and Glu-153.

**Arg-54** and **Glu-144** help to properly position the substrates for the nucleophilic attack

**Glu-153** is hypothesized to play a role in increasing the nucleophilicity of the guanidinium moiety of the substrate via enhanced electronic effects.


**Glu-144** has also been postulated to act as the active site base, abstracting a proton from the reacting arginine either during or immediately after methyl transfer.






## THE BIOCHEMISTRY OF HISTONE ARGININE METHYLATION

PRMT activity requires :  
substrate containing R,  
AdoMet (SAM) as enzymatic cofactor  
PRMT














**S-adenosyl-L-methionine (AdoMet) or (SAM),**



**PRMTs CATALYZE MONO and DIMETHYLATION**  
**- Not trimethylation -**

## PRMT SUBSTRATES AND BIOLOGICAL ACTIVITY

PRMTs can act as activators and repressors of gene expression

| PRMTs:          |   | Type | Histone substrate  | Biological Function   |
|-----------------|---|------|--------------------|---|
| PRMT1           |    | I    | H4R3               | <u>NR, chromatin dynamic, transcription activation</u>                    |
| PRMT2           |    | ?    |                    | Coactivator for ER, Cellular proliferation                                |
| PRMT3           |    | I    |                    | ribosomal biosynthesis  |
| PRMT4           |    | I    | H3R2, H3R17 (Rare) | NR, transcription activation, epigenetic reprogram in embryos             |
| PRMT5           |    | II   | H4R3; H3R8         | <u>Stem cell function, transcription repression, repressive chromatin</u> |
| PRMT6           |    | I    | H3R2               | <u>Repressive chromatin, suppression of H3K4 methylation</u>              |
| PRMT7           |    | II   | H2A, H4R3          | Potentiating DNMT3 binding, regulation of imprinting genes                |
| PRMT8           |   | I    | H4?                | ?   |
| PRMT9 Isoform 4 |  | II   | H4, H2A            | ?   |
| PRMT10          |  | ?    |                    | ?   |
| PRMT11          |  | ?    |                    | ?   |


PRMTs epigenetic writers, are substrate specific and can result in gene repression but also gene activation

→→→

The epigenetic reader that binds to the modified histone R residue at the individual histone tail makes the difference

## HISTONE MODIFICATIONS AND EPIGENETIC READERS

## Protein domains that bind to histone modifications



**Figure 1** Readers of histone PTMs. Recognition of the methylated (me) lysine, methylated (me) arginine, acetylated (ac) lysine and phosphorylated (ph) serine and threonine residues of the N-terminal histone H3 tail by indicated readers.

A large number of proteins contain these protein domains:

→ High complexity in gene regulation that


→ Creation of large numbers of EPIGENOMES

**Table 1** Histone readers and their target PTMs

| Recognition of                    | Reader        | Histone PTM                            |
|-----------------------------------|---------------|--|
| Methyllysine                      | ADD           | H3K9me3                                |
|                                   | Ankyrin       | H3K9me2, H3K9me1                       |
|                                   | BAH           | H4K20me2                               |
|                                   | Chromo-barrel | H3K36me3, H3K36me2, H4K20me1, H3K4me1  |
|                                   | Chromodomain  | H3K9me3, H3K9me2, H3K27me3, H3K27me2   |
|                                   | DCD           | H3K4me3, H3K4me2, H3K4me1              |
|                                   | MBT           | H3Kme1, H3Kme2, H4Kme1, H4Kme2         |
|                                   | PHD           | H3K4me3, H3K4me2, H3K9me3              |
|                                   | PWWP          | H3K36me3, H4K20me1, H4K20me3, H3K79me3 |
|                                   | TTD           | H3K4me3, H3K9me3, H4K20me2             |
| Methylarginine                    | Tudor         | H3K36me3                               |
|                                   | WD40          | H3K27me3, H3K9me3                      |
|                                   | zf-CW         | H3K4me3                                |
| Acetyllysine                      | Bromodomain   | H3Kac, H4Kac, H2AKac, H2BKac           |
|                                   | DBD           | H3KacKac, H4KacKac                     |
|                                   | DPF           | H3Kac                                  |
|                                   | Double PH     | H3K56ac                                |
| Phosphoserine or phosphothreonine | 14-3-3        | H3S10ph, H3S28ph                       |
|                                   | BIR           | H3T3ph                                 |
|                                   | Tandem BRCT   | H2AXS139ph                             |
| Unmodified histone                | ADD           | H3un                                   |
|                                   | PHD           | H3un                                   |
|                                   | WD40          | H3un                                   |

## AN EXAMPLE FOR PRMT FUNCTION IN TRANSCRIPTIONAL ACTIVATION


p53 is a tumor-suppressor  
that acts as transcription factor




- H4R3me stimulates subsequent acetylation of H4
- p53 binds transcription factor binding site in promoter and brings p300.
- p300 acetylates promoter regions
- PRMT4 has affinity for acetylated histones H3R17me
- (note: PRMT1, 4 do not contain a bromo domain → other proteins mediate affinity to acetylated histones)

→ FULL TRANSCRIPTIONAL ACTIVATION


## LYSINE AND ARGININE METHYLATION IN HISTONES IS REVERSIBLE




The **Jumonji N (JmjN)** and **Jumonji C (JmjC)** domains are two non-adjacent domains which have been identified in the jumonji family of transcription factors. Although it was originally suggested that the JmjN and JmjC domains always co-occur and might form a single functional unit within the folded protein, the JmjC domain was latter found without the JmjN domain in organisms from bacteria to human. The JmjC domain is the best studied domain that mediated histone demethylation - is conserved from yeast to human



1. LSD1 (KDM1A): demethylation by oxidation
2. Big family of Jumonji domain containing proteins: hydroxylation




## LYSINE AND ARGININE METHYLATION IN HISTONES IS REVERSIBLE



Histone:  
unmethylated



Histone:  
methylated



### ARTICLE

Received 29 Nov 2015 | Accepted 17 May 2016 | Published 23 Jun 2016

DOI: 10.1038/ncomms10974

OPEN

Arginine demethylation is catalysed by a subset of JmjC histone lysine demethylases

Louise J. Walport<sup>1</sup>, Richard J. Hopkinson<sup>1</sup>, Rasheduzzaman Chowdhury<sup>1</sup>, Rachel Schiller<sup>1</sup>, Wei Ge<sup>1</sup>, Akane Kawamura<sup>1,2</sup> & Christopher J. Schofield<sup>1</sup>

## **LECTURE 4**


### **DNA METHYLATION**

## DNA METHYLATION CONTROLS GENE EXPRESSION

### FACTS:


1. DNA methylation is created at CpG di-nucleotide motifs
2. An accumulation of CpG is called “CpG island” (CGI)
3. CpG islands are enriched at promoters and sequence elements that are important for gene expression control. In some cases, CpG islands can be also located in distant locations.
4. *CpG methylation (=“DNA methylation”) is directly linked with stable gene silencing*

### ADVANTAGE OF DNA METHYLATION AT CpG



CpGs are self-complementary  
Di-nucleotide in paired stand also contains methylation  
Methylation patterns can be maintained during DNA replication


Epigenetic  
modification  
that is imposed  
on genomic **DNA**





## DNA METHYLTRANSFERASES CATALYZE DNA METHYLATION

DNA methyltransferases transfer a methyl-group from AdoMet (SAM) to Cytosine located in a CpG dinucleotide



**S-adenosyl-L-methionine (AdoMet) or (SAM),**



The source of the methyl group is S-adenosyl-L-methionine (AdoMet) or (SAM), which is converted to S-adenosyl-L-homocysteine (AdoHcy) in the reaction.

S-Adenosyl methionine is a common cosubstrate involved in methyl group transfers, transsulfuration, and aminopropylation.

**SAM = enzymatic cofactor**

**SAM is after ATP the most commonly used cofactor used by the cell**

Although these anabolic reactions occur throughout the body, most **SAM-e is produced and consumed in the liver**. More than 40 methyl transfers from SAM-e are known, to various substrates such as nucleic acids, proteins, lipids and secondary metabolites. It is made from adenosine triphosphate (ATP) and methionine by methionine adenosyltransferase. SAM was first discovered in Italy by Giulio Cantoni in 1952.




## Mapping DNA methylation at CpG islands

### BISULFITE SEQUENCING

Methylation of cytosine at CpG dinucleotides is an important epigenetic regulatory modification in many eukaryotic genomes.


DNA methylation was found to be located genome-wide with a pattern of low methylation in proximity to promoters and high genebody-methylation in highly-expressed genes → methylation pattern can identify transcribed DNA (gene)




active  
gene

silenced  
gene


### Bisulfite conversion: C→U conversion



**methyated C cannot  
be converted!!**





DMS = Dimethyl sulfate



Treatment of DNA with bisulfite converts cytosine residues to uracil, but leaves 5-methylcytosine residues unaffected. Thus, bisulfite treatment introduces specific changes in the DNA sequence that depend on the methylation status of individual cytosine residues, yielding single-nucleotide resolution information about the methylation status of a segment of DNA.


## Mapping DNA methylation at CpG islands BISULFITE SEQUENCING

Genomic DNA



Bisulfite  
conversion

DNA for Sequencing



Compare with genomic sequence  
C→U sequence change = DNA methylation  
C→C no sequence change = no DNA methylation

## Mapping DNA methylation at CpG islands BISULFITE SEQUENCING


### An example:

hTERT encodes the telomerase gene  
hTERT elongates telomeres thereby  
protecting cancer cells from  
replicative senescence


→ Cancer cells do not age and can proliferate  
forever!!

→ Therefore 90% of human cancers express  
telomerase. NOTE: telomerase gene is  
silenced by DNA methylation in  
differentiated cells.

→ Bisulfite sequencing showed that cancer  
cells have a de-methylated CpG island  
located at the hTERT promoter. CpG islands  
can overlap with the 1<sup>st</sup> intron of the  
gene!!!!



CANCER CELL  
CpG  
island  
not methylated



NORMAL CELL  
CpG  
island  
is methylated (\*\*)

## Mapping DNA methylation at CpG islands of individual genes

### BISULFITE SEQUENCING

Prepare DNA from normal cell and cancer cell

Purify DNA and perform bi-sulfite conversion (DMS)  
(Unmethylated C → U; Methylated C → C)

Amplify your region of interest = CpG islands  
in the TERT promoter

Purify DNA fragment obtained by PCR



Clone fragment into Plasmid

Transform bacteria with plasmid (one bacteria receives only one plasmid!!!)

Purify amplified plasmids from 10-15 individual bacterial cultures

Sequence inserts using a primer that anneals to the vector DNA,  
adjacent to the insertion site of the PCR product  
REMEMBER: only a single type of plasmid is sequenced  
This refers to a single type of molecule.

To have a good representation, you need to  
sequence at least 10-15 clones



## Mapping DNA methylation at CpG islands BISULFITE SEQUENCING

Prepare DNA from normal cell and cancer cell

Purify DNA and perform bi-sulfite conversion

Amplify your region of interest = CpG islands  
in the TERT promoter

Purify DNA fragment obtained by PCR

Clone fragment into Plasmid

Transform bacteria with plasmid


Purify amplified plasmids

Sequence inserts using a primer that anneals to the vector DNA,  
adjacent the insertion site of the PCR product

**REMEMBER:** only a single type of plasmid is sequenced

This refers to the sequence of interest of a single cell!! To have a good  
representation, you need to sequence at least 10 clones

**IMPORTANT:** Quality control of your bisulfite conversion: ALL C that  
are not followed by G MUST have been converted to U!!!!



Compare with genomic sequence

Bisulfite conversion: C→U sequence change = DNA methylation

C→C no sequence change = no DNA methylation

## Mapping DNA methylation at CpG islands BISULFITE SEQUENCING


### An example:

hTERT encodes the telomerase gene  
Tert elongates telomeres thereby  
protecting cancer cells from  
replicative senescence

→ Cancer cells do not age and can  
proliferate forever!!

→ Therefore 90% of human cancers  
express telomeres; but telomerase is  
silenced by DNA methylation in  
differentiated cells.

→ Bisulfite sequencing showed that  
cancer cells have a de-methylated  
CpG island located at the hTERT  
promoter



## Mapping DNA methylation at CpG islands

### METHYLATED DNA IMMUNOPRECIPITATION: METHYL-DIP

Methyl-DIP works similar to ChIP:

**2 experimental samples:**

- Control (normal cells)
- Experimental sample (cancer cells)

Prepare DNA – carries DNA methylation marks of CpG

Sonicate DNA

Immunoprecipitation using an anti-methyl-CpG specific


Antibody (monoclonal, discriminates between CpG and met-CpG)

Washing of precipitate

DATA ACQUISITION


**Main methods to analyse DNA methylation**

1. PCR on specific CpG islands of interest
2. Differential labelling (Cy3-control; Cy5-cancer methyl-DNA) followed by hybridization to genome array
3. Massive parallel sequencing (different approaches)






## Mapping DNA methylation genome wide: REDUCED REPRESENTATION BISULFITE SEQUENCING (RRBS)




Reduced representation bisulfite sequencing (RRBS) is an efficient and high-throughput technique used to analyze the genome-wide methylation profiles on a single nucleotide level. This technique combines restriction enzymes and bisulfite sequencing in order to enrich for the areas of the genome that have a high CpG content. Due to the high cost and depth of sequencing needed to analyze methylation status in the entire genome. **The fragments that comprise the reduced genome but still includes the majority of promoters, as well as regions such as repeated sequences that are difficult to profile using conventional bisulfite sequencing approaches.**

## Mapping DNA methylation genome wide: REDUCED REPRESENTATION BISULFITE SEQUENCING (RRBS)



The color key from light blue to dark blue indicates the DNA methylation level from low to high, respectively. The white regions in the left panels indicate a lack of DNA methylation information. The red bars in the right panel represent the average DNA methylation level of the corresponding genomic region. The DNA methylation levels were calculated and presented based on 30 kb windows, only if these windows have more than 5 CpG sites covered.

## Mapping DNA methylation genome wide: REDUCED REPRESENTATION BISULFITE SEQUEUNCING (RRBS)



**Enzyme digestion:** First, genomic DNA is digested using a methylation-insensitive restriction enzyme. It is integral for the enzymes to not be influenced by the methylation status of the CpGs (sites within the genome where a cytosine is next to a guanine) as this allows for the digestion of both methylated and unmethylated areas. MspI is commonly used. This enzyme targets 5'CCGG3' sequences and cleaves the phosphodiester bonds upstream of CpG dinucleotide. When using this particular enzyme, each fragment will have a CpG at each end. This digestion results in DNA fragments of various sizes.

**End repair and A-tailing:** Due to the nature of how MspI cleaves double stranded DNA, this reaction results in strands with sticky ends. End repair is necessary to fill in the 3' terminal of the ends of the strands. The next step is adding an extra adenosine to both the plus and minus strands. This is referred to as A-Tailing and is necessary for adapter ligation in the subsequent step. End repair and A-Tailing is done within the same reactions, with dCTP, dGTP and dATP deoxyribonucleotides. In order to increase the efficiency of A tailing, the dATPs are added in excess in this reaction.

**Sequence adapters:** Methylated sequence adapters are ligated to the DNA fragments. The methylated adapter oligonucleotides have all cytosines replaced with 5'methyl-cytosines, in order to prevent the deamination of these cytosines in the bisulfite conversion reaction. For reactions to be sequenced using Illumina sequencers, the sequence adapters are used to hybridize to the adapters on the flow cell.

**Fragment purification:** The desired size of fragments is then selected to be purified. The different sizes of the fragments are separated using gel electrophoresis and are purified using gel excising. According to Gu et al., DNA fragments of 40-220 base pair are representative of the majority of promoter sequences and CpG islands[2].

**Bisulfite conversion:** The DNA fragments are then bisulfite converted, which is a process that deaminates unmethylated cytosine into a uracil. The methylated cytosines remain unchanged, due to the methyl group protecting them from the reaction.

**PCR amplification:** The bisulfite converted DNA is then amplified using PCR with primers that are complementary to the sequence adapters.

**PCR purification:** Before sequencing, the PCR product must be free of unused reaction reagents such as unincorporated dNTPs or salts. Thus, a step for PCR purification is required. This can be done by running another electrophoresis gel or by using kits designed specifically for PCR purification.

**Sequencing:** The fragments are then sequenced. When RRBS was first developed, Sanger sequencing was initially used. Now, next generation sequencing approaches are used. For Illumina sequencing, 36-base single-end sequencing reads are most commonly performed.


**Sequence alignment and analysis:** Due to the unique properties of RRBS, special software is needed for alignment and analysis. Using MspI to digest genomic DNA results in fragments that always start with a C (if the cytosine is methylated) or a T (if a cytosine was not methylated and was converted to a uracil in the bisulfite conversion reaction). This results in a non-random base pair composition. Additionally, the base composition is skewed due to the biased frequencies of C and T within the samples. Various software for alignment and analysis is available, such as Maq, BS Seeker, Bismark or BSMAP. Alignment to a reference genome allows the programs to identify base pairs within the genome that are methylated.

## DNA methyltransferases methylate DNA

### FACTS:

1. DNA methylation is created at CpG di-nucleotide motifs
2. An accumulation of CpG genes is called CpG island
3. CpG islands are enriched at promoters and other, more distant sequence elements that are important for gene expression control
4. CpG methylation (=“DNA methylation”) is linked with Stable gene silencing


### ADVANTAGE OF DNA METHYLATION AT CpG



CpG Di-nucleotide are self-complementary

PROPOSED MODEL:

Methylation patterns can be maintained during DNA replication




**Figure 1.** Cytosine methylation in DNA. (A) Addition of a methyl group,  $\text{CH}_3$  (red), at the five position of the cytosine pyrimidine ring (black arrow) does not sterically interfere with GC base pairing (blue lines). DNA methyltransferases associate covalently with the carbon 6 position (straight green arrow) during methyl group transfer. (B) A model of B-form DNA methylated at cytosines in two self-complementary CpG sequences. The paired methyl moieties (magenta and yellow) lie in the major groove of the double helix.

De-novo DNMTs → place new DNA methylation

Maintenance DNMTs → propagate methylation after replication

## DNA methyl transferases methylate DNA

### Maintenance of DNA methylation patterns by DNMTs



**Figure 2.** De novo methylation and maintenance methylation of DNA. A stretch of genomic DNA is shown as a line with self-complementary CpG pairs marked as vertical strokes. Unmethylated DNA (*top*) becomes methylated "de novo" by Dnmt3a and Dnmt3b to give symmetrical methylation at certain CpG pairs. On semiconservative DNA replication, a progeny DNA strand is base-paired with one of the methylated parental strands (the other replication product is not shown). Symmetry is restored by the maintenance DNA methyltransferase, Dnmt1, which completes half-methylated sites, but does not methylate unmodified CpGs.

### Biochemical discovery of maintenance DNMT1:

Cell extract + DNA containing CpG repeats +  $^{14}\text{C}$  labelled -CH<sub>3</sub> in AdoMet (SAM) → radioactive -CH<sub>3</sub> transferred to DNA

#### NOTE:


This enzyme is 7– to 100-fold more active on hemimethylated DNA as compared with unmethylated substrate *in vitro*

Next step: Purification of enzymatic activity: 200kDa complex containing **DNMT1**

### Discovery of de novo DNMTs:

Sequence of DNMT1 was used to look for genes with similar sequence (sequence homology)


- Discovery of de-novo DNMTs that work efficiently work on un-methylated DNA (DNMT3a, 3b)
- De-novo DNMTs cannot efficiently methylate hemi-methylated DNA



## LOSS OF DNA METHYLTRANSFERASES IS LETHAL DURING EMBRYONIC MOUSE DEVELOPMENT


**Table 1.** Function of mammalian DNA methyltransferases

| DNA methyltransferase | Species | Major activity                 | Major phenotypes of loss of function  |
|-----------------------|---------|--------------------------------|---|
| Dnmt1                 | Mouse   | Maintenance methylation of CpG | Genome-wide loss of DNA methylation, embryonic lethality at embryonic day 9.5 (E9.5), abnormal expression of imprinted genes, ectopic X-chromosome inactivation, activation of silent retrotransposon. In cancer cell lines, it leads to cell cycle arrest and mitotic defects. |
| Dnmt3a                | Mouse   | De novo methylation of CpG     | Postnatal lethality at 4–8 wk, male sterility, and failure to establish methylation imprints in both male and female germ cells   |
| Dnmt3b                | Mouse   | De novo methylation of CpG     | Demethylation of minor satellite DNA, embryonic lethality around E14.5 days with vascular and liver defects. (Embryos lacking both Dnmt3a and Dnmt3b fail to initiate de novo methylation after implantation and die at E9.5.)  |
| DNMT3B                | Human   | De novo methylation of CpG     | ICF syndrome: immunodeficiency, centromeric instability, and facial anomalies. Loss of methylation in repetitive elements and pericentromeric heterochromatin.  |





## DNA METHYLATION IS ABUNDANT IN THE GENOME AND IS SUBJECTED TO DRAMATIC ALTERATIONS DURING EMBRYOGENESIS



**70%- 80% of CpG dinucleotides are methylated in the genome**

DNA methylation levels are high in fertilized Oocytes that contain the paternal and maternal genome (carries characteristic methylation patterns)

Paternal and maternal methylation patterns are rapidly erased (exception: imprinted genes maintain paternal and maternal methylation information). → the paternal and maternal methylation epigenome is cancelled

DNA methylation levels remain low during the first cell division events until the blastocyst stage

In the blastocyst stage cell differentiation programs are activated and genes need to be regulated on the epigenetic level → DNA methylation is increasing (loss of DNMT1, DNMT3a or DNMT3b is lethal → establishment and maintenance of DNA methylation is impaired)

**70%- 80% of CpG di-nucleotides are methylated in the human genome!**

**Remember only 2% of the genome encode for mRNAs**

**98% is noncoding DNA that contains a large proportion of transposable elements, repeat sequences, etc...**

## ON THE SINGLE GENE LEVEL:

**CpG islands (CGIs) are short sequences stretches with variable DNA methylation that regulate promoter activity**

**NOTE: single CpGs are generally hyper methylated (60-90%)**

**CpG islands are differentially methylated, but are generally demethylated**


CpG islands (CGIs) have a length of ca. 1kb

60% of human genes are controlled by CGIs containing promoters that allow tissue/cell specific gene expression

CpG islands can overlap with the first exon (methylation level in 1<sup>st</sup> exon is good predictor of gene expression)

CpG islands located <2kb from promoter: shores

CpG islands located <2-4kb from promoter: shores






## TRANSCRIPTIONAL REGULATION BY METHYL-DNA BINDING PROTEINS


### Interference with transcription factor binding

B



**Figure 1.** Cytosine methylation in DNA. (A) Addition of a methyl group,  $\text{CH}_3$  (red), at the five position of the cytosine pyrimidine ring (black arrow) does not sterically interfere with GC base pairing (blue lines). DNA methyltransferases associate covalently with the carbon 6 position (straight green arrow) during methyl group transfer. (B) A model of B-form DNA methylated at cytosines in two self-complementary CpG sequences. The paired methyl moieties (magenta and yellow) lie in the major groove of the double helix.

Methylated DNA obtains different structure:  
Transcription factors cannot bind anymore  
→ DNA methylation sensitive transcription factors



Example: CTCF

Unmethylated DNA CTCF binds → activation of expression

Methylated DNA: CTCF does not bind → no activation

Note: CTCF is a major epigenetic regulator that is involved in controlling genomic imprinting, enhance activation,...


## EPIGENETIC READERS OF DNA METHYLATION

### Transcriptional regulation by methyl-dna binding proteins

Table 2. Functions of methyl-CpG binding proteins



| MBP   | Major activity  | Species | Major phenotypes of loss-of-function mutations   |
|-------|---|---------|--|
| MeCP2 | Binds mCpG with adjacent run AT-rich run Transcriptional repressor  | Mouse   | Delayed onset neurological defects including inertia, hind-limb claspings, nonrhythmic breathing, and abnormal gait. Postnatal survival ~10 wk.  |
| MECP2 | Binds mCpG with adjacent AT run Transcriptional repressor   | Human   | Heterozygotes suffer from Rett syndrome, a profound neurological disorder characterized by apraxia, loss of purposeful hand use, breathing irregularities, and microcephaly  |
| Mbd1  | Binds mCpG via MBD; a major splice form is also able to bind CpG via a CxxC domain  | Mouse   | No overt phenotype, but subtle defects in neurogenesis detected  |
| Mbd2  | Binds mCpG Transcriptional repressor  | Mouse   | Viable and fertile, but show reduced maternal nurturing behavior. Defective gene regulation in T-helper cell differentiation leading to altered response to infection. Highly resistant to intestinal tumorigenesis.                                   |
| Mbd3  | Core component of NuRD corepressor complex Does not show strong binding to mCpG   | Mouse   | Early embryonic lethal   |
| Mbd4  | DNA repair protein that binds mCpG and T:G mismatches at mCpG sitesThymine DNA glycosylase that excises T from T:G mismatches | Mouse   | Viable and fertile. three- to fourfold increase in mutations at CpG sites. Increased susceptibility to intestinal cancer correlates with C to T transitions within the <i>Apc</i> gene. Mbd4 functions to minimize the mutability of 5-methylcytosine. |
| Kaiso | Binds mCGmCG and CTGCNA Transcriptional repressor   | Mouse   | No overt phenotype. Small but significant delay in tumorigenesis on Min background.  |

Several proteins were identified to have affinity to methylated CpG but do not have affinity to unmethylated CpG → mediate transcriptional silencing  
 → CpG METHYL BINDING DOMAIN PROTEIN (MBD) FAMILY : MeCP1, MeCP2, Mbd1, Mbd2, Mbd2, Mbd4  
 → Kaiso (unrelated protein)



# How does MeCP2 effect the brain function?

- Through it's job as a reader of epigenetic bookmarks
- The wide array of functions that MeCP2 performs ALL contribute to Rett syndrome.
- The different mutations have different effects on the presentation of the disease.
- In addition since each person is different based on their personal epigenetics, the disease will be individual as well.



## Figure 1 Composition of MeCP2: gene structure, splicing patterns and putative functional domains

**(A)** Splicing patterns generating the two mRNA isoforms of *MECP2*, *\_e1* and *\_e2*. The two isoforms generate two protein isoforms of MeCP2 with differing N-termini due to the use of alternative translation start sites (bent arrows) and the absence or presence of exon 2 in the transcript. **(B)** Apart from the N-terminus, both MeCP2 isoforms are identical and contain several functionally distinct domains: NTD, N-terminal domain; MBD, methylated DNA-binding domain; ID, interdomain; TRD, transcription repression domain; CTD, C-terminal domain; NLS; nuclear localization signals. Locations of seven of the most common point mutations in RTT are indicated (◆). Below each domain are indicated major (bold) and other (grey) interactors and functions. HP1, heterochromatin protein 1; TFIIB, transcription factor IIB; YB1, Y-box-binding protein 1.

## EPIGENETIC READERS OF DNA METHYLATION

## Transcriptional regulation by methyl-dna binding proteins

Table 2. Functions of methyl-CpG binding proteins

| MBP   | Major activity  | Species | Major phenotypes of loss-of-function mutations   |
|-------|---|---------|--|
| MeCP2 | Binds mCpG with adjacent run AT-rich run Transcriptional repressor  | Mouse   | Delayed onset neurological defects including inertia, hind-limb clasping, nonrhythmic breathing, and abnormal gait. Postnatal survival ~10 wk.   |
| MECP2 | Binds mCpG with adjacent AT run Transcriptional repressor   | Human   | Heterozygotes suffer from Rett syndrome, a profound neurological disorder characterized by apraxia, loss of purposeful hand use, breathing irregularities, and microcephaly  |
| Mbd1  | Binds mCpG via MBD; a major splice form is also able to bind CpG via a CxxC domain  | Mouse   | No overt phenotype, but subtle defects in neurogenesis detected  |
| Mbd2  | Binds mCpG Transcriptional repressor  | Mouse   | Viable and fertile, but show reduced maternal nurturing behavior. Defective gene regulation in T-helper cell differentiation leading to altered response to infection. Highly resistant to intestinal tumorigenesis.                                   |
| Mbd3  | Core component of NuRD corepressor complex Does not show strong binding to mCpG   | Mouse   | Early embryonic lethal   |
| Mbd4  | DNA repair protein that binds mCpG and T:G mismatches at mCpG sitesThymine DNA glycosylase that excises T from T:G mismatches | Mouse   | Viable and fertile. three- to fourfold increase in mutations at CpG sites. Increased susceptibility to intestinal cancer correlates with C to T transitions within the <i>Apc</i> gene. Mbd4 functions to minimize the mutability of 5-methylcytosine. |
| Kaiso | Binds mCGmCG and CTGCNA Transcriptional repressor   | Mouse   | No overt phenotype. Small but significant delay in tumorigenesis on Min background.  |


Methyl-CpG binding proteins are present in transcriptional co-repressor complexes

**MeCP2:** component of the Sin3A HDAC complex

**Mbd3:** component of the NuRD HDAC complex

**Mbd1:** interacts with HDAC3. Mbd1 and HDAC3 are recruited by the PML-RARalpha hybrid protein to silence gene expression in Acute promyelocytic leukemia


**MBD1:** interacts with the H3K9 HMTase SETDB1



Collaboration to repress genes

## TRANSCRIPTIONAL REGULATION BY METHYL-DNA BINDING PROTEINS

### RECRUITMENT OF Methyl-CpG binding proteins and co-repressor complexes



**MeCP2: components of the Sin3A HDAC complex**

**Mbd3: component of the NuRD HDAC complex**

**Mbd1: interacts with HDAC3.**

**Example: Mbd1 and HDAC3 are recruited by the PML-RARalpha hybrid protein (specialized transcription factor) to silence gene expression in cancer**

**MBD1: interacts with the H3K9me3 HMTase SETDB1**

DNA methylation collaborates with other chromatin modifying complexes to repress gene expression

**Figure 9.** Recruitment of corepressors by methyl-CpG binding proteins. A hypothetical transition between an active, nonmethylated gene promoter and a repressed promoter whose silence is attributable to DNA methylation, as mediated by complexes containing an MBD protein such as MeCP2 (gray shading). The transition phase represents an intermediate step during which transcription is silenced and DNA methylation occurs. MeCP2 is envisaged to recruit the NCoR histone deacetylase (HDAC) complex and histone lysine methyltransferase (HKMT) activity to the methylated sites.



## ON THE SINGLE GENE LEVEL:

**CpG islands (CGIs) are short sequences stretches with variable DNA methylation that regulate promoter activity**

**NOTE: single CpGs are generally hyper methylated (60-90%)**

**CpG islands are differentially methylated, but are generally demethylate**


CpG islands (CGIs) have a length of ca. 1kb

60% of human genes are controlled by CGIs containing promoters that allow tissue/cell specific gene expression


CpG islands can overlap with the first exon (methylation level in 1<sup>st</sup> exon is good predictor of gene expression)

CpG islands located <2kb from promoter: shores

CpG islands located <2-4kb from promoter: shores



## DNA METHYLATION IS ABUNDANT IN THE GENOME AND IS SUBJECT TO DRAMATIC ALTERATIONS DURING EMBRYOGENESIS



DNA methylation levels are high in fertilized Oocytes that contain the paternal and maternal genome (carries characteristic methylation patterns)

Paternal and maternal methylation patterns are rapidly erased (exception: imprinted genes maintain paternal and maternal methylation information). → the paternal and maternal methylation epigenome is cancelled

DNA methylation levels remain low during the first cell division events until the blastocyst stage

In the blastocyst stage cell differentiation programs are activated and genes need to be regulated on the epigenetic level → DNA methylation is increasing (loss of DNMT1, DNMT3a or DNMT3b is lethal → establishment and maintenance of DNA methylation is impaired)


**70%- 80% of CpG dinucleotides are methylated in the genome**

**60%- 90% of CpG di-nucleotides are methylated in the human genome!**

**Remember only 2% of the genome encode for mRNAs**


**CpG islands are differentially methylated**

## DNA METHYLATION IS REVERSIBLE: DNA DEMETHYLATION BY Tet-family proteins



**Figure 6.** Model of Tet-initiated DNA demethylation pathways. DNA methylation (5mC) is established and maintained by DNMT. 5mC can be oxidized by Tet family of dioxygenases to generate 5hmC, 5fC, and 5caC. Because the oxidized 5mC derivatives cannot serve as substrates for DNMT1, they can be lost by replication-dependent passive demethylation. 5hmC can be deaminated by AID/APOBEC to become 5hmU, which together with 5fC and 5caC can be excised by glycosylases such as TDG, followed by DNA repair to generate C. Alternatively, a putative decarboxylase may convert 5caC to C.

### Tet-family proteins mediate DNA demethylation




5mC, 5hmC and 5fC are abundant in the cell  
5caC is present only at very low abundance


**DNMT1 has exclusive specificity for 5mC**




## DNA METHYLATION IS REVERSIBLE: DNA DEMETHYLATION BY Tet-family proteins



**Figure 6.** Model of Tet-initiated DNA demethylation pathways. DNA methylation (5mC) is established and maintained by DNMT. 5mC can be oxidized by Tet family of dioxygenases to generate 5hmC, 5fC, and 5caC. Because the oxidized 5mC derivatives cannot serve as substrates for DNMT1, they can be lost by replication-dependent passive demethylation. 5hmC can be deaminated by AID/APOBEC to become 5hmU, which together with 5fC and 5caC can be excised by glycosylases such as TDG, followed by DNA repair to generate C. Alternatively, a putative decarboxylase may convert 5caC to C.




The protein encoded by this gene belongs to the TDG/mug DNA glycosylase family. Thymine-DNA glycosylase (TDG) removes thymine moieties from G/T mismatches by hydrolyzing the carbon-nitrogen bond between the sugar-phosphate backbone of DNA and the mispaired thymine. With lower activity, this enzyme also removes thymine from C/T and T/T mispairings. TDG can also remove uracil and 5-bromouracil from mispairings with guanine. Interestingly, TDG knockout mouse models showed no increase in mispairing frequency suggesting that other enzymes, like the functional homologue MBD4, may provide functional redundancy. This gene may have a pseudogene in the p arm of chromosome 12. Additionally, in 2011, the human thymine DNA glycosylase (hTDG) was reported to efficiently excise 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), the key oxidation products of 5-methylcytosine in genomic DNA. Later on, the crystal structure of the hTDG catalytic domain in complex with duplex DNA containing 5caC was published, which supports the role of TDG in mammalian 5-methylcytosine demethylation.



Check textbooks: glycosilases cleave off bases from sugar → apyrimidic/apurinic site → BER pthway

# DNA METHYLATION IS REVERSIBLE: ACTIVE AND PASSIVE DNA DEMETHYLATION

## DNA de-methylation of the paternal and maternal genome has different kinetics



## PASSIVE DNA DEMETHYLATION

Successive rounds of DNA methylation reduce the amount of 5mC. In this situation DNMT1 is excluded from the Nucleus! (only transient presence of oocyte specific version of DNMT1 at the 8 cell stage)

**MATERNAL GENOME:** slow de-methylation of DNA

## ACTIVE DNA DEMETHYLATION

Enzymatic activity rapidly de-methylates 5mC

**PATERNAL GENOME:** fast de-methylation of DNA

- **In zygotes Tet3 is localized to the PATERNAL nucleus**
- **Paternal DNA is demethylated**
- **High levels of 5hmC: 5-hydroxymethylcytosine, 5fc: 5-formylcytosine and 5caC: 5-carboxylcytosine were detected at high levels in the paternal nucleus**
- **BER machinery concentrated in pronucleus**

